| 臺大學術典藏 |
2022-02-18T08:25:53Z |
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial
|
Hsu Y.-C.; Chen C.-Y.; Chang I.-W.; Chang C.-Y.; Wu C.-Y.; Lee T.-Y.; Wu M.-S.; Bair M.-J.; Chen J.-J.; CHIEH-CHANG CHEN; Tseng C.-H.; Tai C.-M.; Huang Y.-T.; Ku W.-H.; Mo L.-R.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-18T06:28:59Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; WEN-FENG HSU; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-18T06:28:58Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; WEN-FENG HSU; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T06:28:57Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chen C.-C.; Chen C.-C.; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; WEN-FENG HSU; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T06:28:56Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; WEN-FENG HSU; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T06:28:55Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; WEN-FENG HSU; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-18T06:28:53Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; WEN-FENG HSU; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:55Z |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chang C.-Y.; YU-JEN FANG; Lee J.-Y.; Sheng W.-H.; Wang H.-P.; Wu M.-S.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-14T06:28:53Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chen M.-J.; Chen C.-C.; Chang C.-Y.; YU-JEN FANG; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:53Z |
Randomised clinical trial: High-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers
|
Chen C.-C.; Lee J.-Y.; YU-JEN FANG; Hsu S.-J.; Han M.-L.; Tseng P.-H.; Liou J.-M.; Hu F.-C.; Lin T.-L.; Wu M.-S.; Wang H.-P.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-14T06:28:52Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; YU-JEN FANG; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:52Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; YU-JEN FANG; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2022-02-14T06:28:51Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
YU-JEN FANG; Liou J.-M.; Chen C.-C.; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chen C.-C.; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:51Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; Chen C.-C.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; YU-JEN FANG; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2022-02-14T06:28:50Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; YU-JEN FANG; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:50Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Kao J.-H.; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; YU-JEN FANG; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2022-02-14T06:28:49Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; YU-JEN FANG; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chen C.-C.; Chen C.-C.; YU-JEN FANG; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chen C.-C.; Chen Y.-N.; Chen C.-C.; YU-JEN FANG; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:48Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; Chen C.-C.; YU-JEN FANG; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:47Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; YU-JEN FANG; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-02-14T06:28:46Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; YU-JEN FANG; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2022-01-25T07:24:19Z |
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial
|
Hsu Y.-C.; Chen C.-Y.; Chang I.-W.; Chang C.-Y.; Wu C.-Y.; Lee T.-Y.; MING-SHIANG WU; Bair M.-J.; Chen J.-J.; Chen C.-C.; Tseng C.-H.; Tai C.-M.; Huang Y.-T.; Ku W.-H.; Mo L.-R.; Lin J.-T. |
| 國立成功大學 |
2022 |
Impact of Adjuvant Chemotherapy on Variant Histology of Upper Tract Urothelial Carcinoma: A Propensity Score-Matched Cohort Analysis
|
Lo, C.-W.;Li, W.-M.;Ke, H.-L.;Chang, Y.-H.;Wu, H.-C.;Chen, I.-H.A.;Lin, J.-T.;Huang, C.-Y.;Chen, Chen C.-H.;Tseng, J.-S.;Lin, W.-R.;Jiang, Y.-H.;Lee, Y.-K.;Tsai, C.-Y.;Chung, S.-D.;Hsueh, T.Y.;Chiu, A.W.;Jou, Y.-C.;Cheong, I.-S.;Chen, Y.-T.;Chen, J.-S.;Chiang, B.-J.;Yu, C.-C.;Lin, W.Y.;Wu, C.-C.;Chen, Chen C.-S.;Weng, H.-Y.;Tsai, Y.-C. |
| 國立成功大學 |
2022 |
A Fast Multidimensional Data Fusion Algorithm for Hyperspectral Spatiotemporal Super-Resolution
|
Chang, P.-C.;Lin, J.-T.;Lin, C.-H.;Tang, P.-W.;Liu, Y. |
| 國立成功大學 |
2022 |
Real-Time Hyperspectral Anomaly Detection using Collaborative Superpixel Representation with Boundary Refinement
|
Lin, J.-T.;Lin, C.-H. |
| 臺大學術典藏 |
2021-12-01T06:03:28Z |
Hepatic lymphoma mimicking liver abscess: Report of a case and review of the literature
|
Wu M.-S.; Lin J.-T.; Yang P.-M.; YEE-CHUN CHEN; Su I.-J.; Wang T.-H. |
| 臺大學術典藏 |
2021-12-01T02:30:26Z |
Low prevalence of Helicobacter pylori but high prevalence of cytomegalovirus-associated peptic ulcer disease in AIDS patients: Comparative study of symptomatic subjects evaluated by endoscopy and CD4 counts
|
Chiu H.-M.; Wu M.-S.; CHIEN-CHING HUNG; Shun C.-T.; Lin J.-T. |
| 臺大學術典藏 |
2021-11-18T04:58:19Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; Hsu C.-H; Lin J.-K; Hsu M.-M; Ho Y.-F; She T.-S; JENG-YUH KO; Lin J.-T; Lin B.-R; Wu M.-S; Yu H.-S; Jee S.-H; Chen G.-S; Chen T.-M; Chen C.-A; Lai M.-K; Pu Y.-S; Pan M.-H; Wang Y.-J; Tsai C.-C; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-11-18T04:58:11Z |
Transnasal endoscopy with narrow-band imaging and Lugol staining to screen patients with head and neck cancer whose condition limits oral intubation with standard endoscope (with video)
|
Lee Y.-C; Wang C.-P; Chen C.-C; Chiu H.-M; JENG-YUH KO; Lou P.-J; Yang T.-L; Huang H.-Y; Wu M.-S; Lin J.-T; Hsiu-Hsi Chen T; Wang H.-P. |
| 臺大學術典藏 |
2021-11-18T04:58:08Z |
Risk factors for developing synchronous esophageal neoplasia in patients with head and neck cancer
|
Wang W.-L; Lee C.-T; Lee Y.-C; Hwang T.-Z; Wang C.-C; Hwang J.-C; Tai C.-M; Chang C.-Y; Tsai S.-S; Wang C.-P; JENG-YUH KO; Lin J.-T. |
| 臺大學術典藏 |
2021-11-18T04:58:07Z |
Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: Better risk assessment with epigenetic markers
|
Lee Y.-C; Wang H.-P; Wang C.-P; JENG-YUH KO; Lee J.-M; Chiu H.-M; Lin J.-T; Yamashita S; Oka D; Watanabe N; Matsuda Y; Ushijima T; Wu M.-S. |
| 臺大學術典藏 |
2021-11-18T04:58:01Z |
Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions
|
Lee Y.-C; Chiu H.-M; Chiang T.-H; Yen A.M.-F; Chiu S.Y.-H; Chen S.L.-S; Fann J.C.-Y; Yeh Y.-P; Liao C.-S; Hu T.-H; Tu C.-H; Tseng P.-H; Chen C.-C; Chen M.-J; Liou J.-M; Liao W.-C; Lai Y.-P; Wang C.-P; JENG-YUH KO; Wang H.-P; Chiang H; Lin J.-T; Chen H.-H; Wu M.-S. |
| 臺大學術典藏 |
2021-11-18T04:58:01Z |
The benefit of pretreatment esophageal screening with image-enhanced endoscopy on the survival of patients with hypopharyngeal cancer
|
Wang W.-L; Wang C.-P; Wang H.-P; Lee C.-T; Chang C.-Y; Tai C.-M; Tseng C.-H; Hwang T.-Z; Wang C.-C; Lo J.-L; Tseng P.-H; Chiu H.-M; Lee J.-M; JENG-YUH KO; Lou P.-J; Wu M.-S; Lee Y.-C; Lin J.-T. |
| 臺大學術典藏 |
2021-11-15T07:48:43Z |
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
|
Chen A.-L; Hsu C.-H; Lin J.-K; Hsu M.-M; Ho Y.-F; She T.-S; JENG-YUH KO; Lin J.-T; Lin B.-R; Wu M.-S; Yu H.-S; Jee S.-H; Chen G.-S; Chen T.-M; Chen C.-A; Lai M.-K; Pu Y.-S; Pan M.-H; Wang Y.-J; Tsai C.-C; Hsieh C.-Y. |
| 臺大學術典藏 |
2021-11-15T07:48:34Z |
Transnasal endoscopy with narrow-band imaging and Lugol staining to screen patients with head and neck cancer whose condition limits oral intubation with standard endoscope (with video)
|
Lee Y.-C; Wang C.-P; Chen C.-C; Chiu H.-M; JENG-YUH KO; Lou P.-J; Yang T.-L; Huang H.-Y; Wu M.-S; Lin J.-T; Hsiu-Hsi Chen T; Wang H.-P. |
| 臺大學術典藏 |
2021-11-15T07:48:31Z |
Risk factors for developing synchronous esophageal neoplasia in patients with head and neck cancer
|
Wang W.-L; Lee C.-T; Lee Y.-C; Hwang T.-Z; Wang C.-C; Hwang J.-C; Tai C.-M; Chang C.-Y; Tsai S.-S; Wang C.-P; JENG-YUH KO; Lin J.-T. |
| 臺大學術典藏 |
2021-11-15T07:48:29Z |
Revisit of field cancerization in squamous cell carcinoma of upper aerodigestive tract: Better risk assessment with epigenetic markers
|
Lee Y.-C; Wang H.-P; Wang C.-P; JENG-YUH KO; Lee J.-M; Chiu H.-M; Lin J.-T; Yamashita S; Oka D; Watanabe N; Matsuda Y; Ushijima T; Wu M.-S. |
| 臺大學術典藏 |
2021-11-15T07:48:23Z |
The benefit of pretreatment esophageal screening with image-enhanced endoscopy on the survival of patients with hypopharyngeal cancer
|
Wang W.-L; Wang C.-P; Wang H.-P; Lee C.-T; Chang C.-Y; Tai C.-M; Tseng C.-H; Hwang T.-Z; Wang C.-C; Lo J.-L; Tseng P.-H; Chiu H.-M; Lee J.-M; JENG-YUH KO; Lou P.-J; Wu M.-S; Lee Y.-C; Lin J.-T. |
| 臺大學術典藏 |
2021-11-15T07:48:22Z |
Accuracy of faecal occult blood test and Helicobacter pylori stool antigen test for detection of upper gastrointestinal lesions
|
Lee Y.-C; Chiu H.-M; Chiang T.-H; Yen A.M.-F; Chiu S.Y.-H; Chen S.L.-S; Fann J.C.-Y; Yeh Y.-P; Liao C.-S; Hu T.-H; Tu C.-H; Tseng P.-H; Chen C.-C; Chen M.-J; Liou J.-M; Liao W.-C; Lai Y.-P; Wang C.-P; JENG-YUH KO; Wang H.-P; Chiang H; Lin J.-T; Chen H.-H; Wu M.-S. |
| 臺大學術典藏 |
2021-10-18T06:30:00Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; Chen C.-C.; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chen C.-C.; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; YEN-NIEN CHEN; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:30:00Z |
Systematic review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chen C.-C.; YEN-NIEN CHEN; Chen C.-C.; Fang Y.-J.; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:29:59Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; Chen C.-C.; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chen C.-C.; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; YEN-NIEN CHEN; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:29:58Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; Chen C.-C.; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chen C.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; YEN-NIEN CHEN; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2021-10-18T06:29:57Z |
Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands
|
Chiang T.-H.; Maeda M.; Yamada H.; Chan C.-C.; Chen S.L.-S.; Chiu S.Y.-H.; YEN-NIEN CHEN; Chou Y.-H.; Shieh C.-F.; Liu C.-Y.; Chiu H.-M.; Chiang H.; Shun C.-T.; Lin M.-W.; Wu M.-S.; Lin J.-T.; Chen H.-H.; Ushijima T.; Graham D.Y.; Lee Y.-C. |
| 臺大學術典藏 |
2021-09-15T06:19:22Z |
Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: A long-term cohort study on Matsu Islands
|
Chiang T.-H.; Chang W.-J.; Chen S.L.-S.; Yen A.M.-F.; Fann J.C.-Y.; Chiu S.Y.-H.; Chen Y.-R.; Chuang S.-L.; Shieh C.-F.; Liu C.-Y.; Chiu H.-M.; Chiang H.; Shun C.-T.; Lin M.-W.; Wu M.-S.; Lin J.-T.; CHANG-CHUAN CHAN; Graham D.Y.; Chen H.-H.; Lee Y.-C. |
| 臺大學術典藏 |
2021-09-15T06:19:21Z |
Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands
|
Chiang T.-H.; Maeda M.; Yamada H.; CHANG-CHUAN CHAN; Chen S.L.-S.; Chiu S.Y.-H.; Chen Y.-N.; Chou Y.-H.; Shieh C.-F.; Liu C.-Y.; Chiu H.-M.; Chiang H.; Shun C.-T.; Lin M.-W.; Wu M.-S.; Lin J.-T.; Chen H.-H.; Ushijima T.; Graham D.Y.; Lee Y.-C. |
| 臺大學術典藏 |
2021-09-04T06:24:17Z |
Acute pancreatitis complicated by infarction of the spleen and spinal cord
|
Wei S.-C.; JIA-HORNG KAO; Lee W.-Y.; Lin J.-T.; Wang T.-H. |
| 臺大學術典藏 |
2021-09-04T06:11:10Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; JIA-HORNG KAO; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; Chen C.-C.; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2021-09-04T06:11:00Z |
Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Yang T.-H.; JIA-HORNG KAO; Chen C.-C.; Tseng C.-H.; Tai C.-M.; Lin C.-W.; Wu C.-Y.; Lin J.-T. |
